These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31539045)

  • 1. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 2. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering nutraceuticals update on scientific evidence.
    Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Kołodziejczak M; Navarese EP
    Atherosclerosis; 2016 Apr; 247():189-92. PubMed ID: 26926598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinician Decision Support Tools: Advances in Lipid-Lowering Treatment Intensification.
    Marvel FA; Grant JK; Martin SS
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010884. PubMed ID: 38634283
    [No Abstract]   [Full Text] [Related]  

  • 14. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery.
    Zafrir B; Saliba W; Jaffe R; Sliman H; Flugelman MY; Sharoni E
    Eur J Prev Cardiol; 2019 Mar; 26(4):401-408. PubMed ID: 30426772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.
    Ridker PM
    Circulation; 2018 Apr; 137(17):1763-1766. PubMed ID: 29273581
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipids and antithrombotic treatment.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):71. PubMed ID: 32176294
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study.
    Bittencourt MS; Blankstein R; Blaha MJ; Sandfort V; Agatston AS; Budoff MJ; Blumenthal RS; Krumholz HM; Nasir K
    Eur J Prev Cardiol; 2018 Nov; 25(17):1887-1898. PubMed ID: 30043629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.
    Schiele F; Ecarnot F; Chopard R
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):88-100. PubMed ID: 28618915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose and LDL lowering: the need for intensive therapy.
    Del Prato S
    Curr Vasc Pharmacol; 2012 Nov; 10(6):687-9. PubMed ID: 23259554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.